TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Medicine, Oncology, Pharmacology +16

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

Peter Goldstraw, Kari Chansky, John Crowley et al. · Journal of Thoracic Oncology · 2016 · 4.6K citations · Full text

Medicine, Oncology, Surgery +11

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pieter E. Postmus, Keith M. Kerr, Matthijs Oudkerk et al. · Annals of Oncology · 2017 · 2.3K citations · Full text

Medicine, Oncology, Surgery +14

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu et al. · Cancer Discovery · 2014 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +13